Our research and development activity is headquartered in Parma, Italy. Additionally, there are six other major research centers located in Chippenham (UK), Paris (France), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada).
Our research and development programmes combine technical advances, scientific expertise and patient insight to drive improved solutions that can positively impact the health and quality of life of our patients.
We invest in innovation
Chiesi’s turnover stems from internal research, but the pipeline also includes products that arise from collaborations and partnerships with other companies.
24% of our turnover is reinvested into research and development.
85M euros investment in our Biotech Center of Excellence in Parma, Italy. The center will be dedicated to the development, production, and distribution of biological therapies.
We intend to maintain our focus on our three primary disease areas - air, rare and care - while also expanding our research & development programmes to diversify and improve our range of therapies. This helps us achieve a balanced pipeline that features both promising studies with the potential for important breakthroughs and practical solutions for patients with unmet needs.
clinical trial transparency
We have a crucial responsibility to ensure the safety and well-being of our patients, which we fulfill by adopting a patient-centric approach across all our operations. Transparency is an integral part of this approach, starting with the way we increase and broaden access to data from our clinical research.
Chiesi is committed to clinical trial transparency and is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Association of the British Pharmaceutical Industry (ABPI). In the UK, clinical trials and non-interventional studies of marketed medicines are recorded in line with the ABPI Code of Practice. All Chiesi Group studies are recorded in accordance with the local legislative and applicable requirements on clinical studies.
The Chiesi Clinical Study Register
The Chiesi Clinical Study Register contains detailed, up-to-date information on the clinical studies we carry out – including their phase, status, and all related publications.
The Register includes the Clinical Study Report (CSR) synopses of clinical studies sponsored by Chiesi submitted to the Food and Drug Administration (FDA), the European Medicines Agency (EMA) or National Competent Authorities.
Chiesi provides the CSR Synopses consistently in line with all laws around patient privacy, publication rights, and commercially confidential information, through appropriate redaction.
We also encourage and support the submission of publications in scientific journals of results from all phase 3 clinical trials sponsored by Chiesi Farmaceutici S.p.A as a minimum, and any clinical study results of significant medical importance, regardless of the outcome.
Data sharing registries
We disclose clinical protocols, study-related information and summary results of clinical studies sponsored by Chiesi Farmaceutici S.p.A. and Chiesi Italia S.p.A. in global public registries.
Notably, we commit to disclose information regarding any phase 2-4 clinical trial, specific typologies of non-interventional studies, and clinical investigations on medical devices sponsored by Chiesi Farmaceutici S.p.A. and Chiesi Italia S.p.A. within 12 months from completion of the study.
Resources and useful links
UK-CHI-2500074 | January 2025
